Development of Angiogenesis Inhibitors to Vascular Endothelial Growth Factor Receptor 2 for Cancer Therapy

2007 ◽  
pp. 333-382
Author(s):  
Keren Paz ◽  
Zhenping Zhu
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cancer Therapy ◽  
Growth Factor Receptor ◽  
Angiogenesis Inhibitors ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

scholarly journals Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy

2007 ◽  
Vol 13 (18) ◽  
pp. 5544s-5548s ◽  
Author(s):  
Hagop Youssoufian ◽  
Daniel J. Hicklin ◽  
Eric K. Rowinsky
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Monoclonal Antibodies ◽  
Growth Factor ◽  
Cancer Therapy ◽  
Growth Factor Receptor ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

Vascular Endothelial Growth Factor Receptor as Target for Advanced Non-Small Cell Lung Cancer Therapy

2010 ◽  
Vol 11 (7) ◽  
pp. 865-874 ◽  
Author(s):  
Antonio Rossi ◽  
Paolo Maione ◽  
Paola Claudia Sacco ◽  
Rita Ambrosio ◽  
Marzia Falanga ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cancer Therapy ◽  
Growth Factor Receptor ◽  
Small Cell ◽  
Vascular Endothelial ◽  
Small Cell Lung ◽  
Lung Cancer Therapy ◽  
Endothelial Growth Factor

Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Inhibitors as Anti-Angiogenic Agents in Cancer Therapy

2007 ◽  
Vol 2 (1) ◽  
pp. 59-71 ◽  
Author(s):  
Anand Veeravagu ◽  
Andrew Hsu ◽  
Weibo Cai ◽  
Lewis Hou ◽  
Victor Tse ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cancer Therapy ◽  
Growth Factor Receptor ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System

2015 ◽  
Vol 29 (2) ◽  
pp. 158-162 ◽  
Author(s):  
Antonella Moreo ◽  
Paola Vallerio ◽  
Riccardo Ricotta ◽  
Miriam Stucchi ◽  
Mattia Pozzi ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cancer Therapy ◽  
Cardiovascular System ◽  
Growth Factor Receptor ◽  
Central Blood Pressure ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

Rationale for Antiangiogenic Cancer Therapy with Vaccination Using Epitope Peptides Derived from Human Vascular Endothelial Growth Factor Receptor 2

2005 ◽  
Vol 65 (11) ◽  
pp. 4939-4946 ◽  
Author(s):  
Satoshi Wada ◽  
Takuya Tsunoda ◽  
Toshiyuki Baba ◽  
F. James Primus ◽  
Hiroyuki Kuwano ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cancer Therapy ◽  
Growth Factor Receptor ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

Vascular Endothelial Growth Factor Receptor as Target for Advanced Non-Small Cell Lung Cancer Therapy

2010 ◽  
Vol 999 (999) ◽  
pp. 1-10
Author(s):  
Antonio Rossi ◽  
Paolo Maione ◽  
Paola Claudia Sacco ◽  
Rita Ambrosio ◽  
Marzia Falanga ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cancer Therapy ◽  
Growth Factor Receptor ◽  
Small Cell ◽  
Vascular Endothelial ◽  
Small Cell Lung ◽  
Lung Cancer Therapy ◽  
Endothelial Growth Factor

Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2

Blood ◽  
2003 ◽  
Vol 102 (5) ◽  
pp. 1815-1823 ◽  
Author(s):  
Ji-yan Liu ◽  
Yu-quan Wei ◽  
Li Yang ◽  
Xia Zhao ◽  
Ling Tian ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cancer Therapy ◽  
Antitumor Activity ◽  
Growth Factor Receptor ◽  
Endothelial Cell Proliferation ◽  
Vascular Endothelial ◽  
Protein Vaccine ◽  
Homologous Protein ◽  
Endothelial Growth Factor

AbstractThe breaking of immune tolerance of “self-antigens” associated with angiogenesis is an attractive approach to cancer therapy by active immunity. We used vascular endothelial growth factor receptor-2 (VEGFR-2) as a model antigen to explore the feasibility of the immunotherapy with a vaccine based on a xenogeneic homologous protein. To test this concept, we prepared a quail homologous VEGFR-2 protein vaccine (qVEGFR) based on quail VEGFR-2. At the same time, a protein vaccine based on the corresponding ligand-binding domain of mouse self-VEGFR-2 (mVEGFR) was also prepared and used as a control. We found that immunotherapy with qVEGFR was effective at protective and therapeutic antitumor immunity in several solid and hematopoietic tumor models in mice. Autoantibodies against mouse VEGFR-2 (Flk-1) were identified by Western blot analysis and enzyme-linked immunosorbent assay (ELISA). Anti-VEGFR antibody-producing B cells were detectable by ELISPOT. Endothelial deposition of immunoglobulins developed within tumor. VEGF-mediated endothelial cell proliferation was inhibited in vitro by immunoglobulins from qVEGFR-immunized mice. Antitumor activity was caused by the adoptive transfer of the purified immunoglobulins. Antitumor activity and production of autoantibodies against Flk-1 could be abrogated by the depletion of CD4+ T lymphocytes. Angiogenesis was apparently inhibited within the tumors, and the vascularization of alginate beads was also reduced. No marked toxicity was found in the immunized mice. The observations may provide a vaccine strategy for cancer therapy through the induction of autoimmunity against the growth factor receptor associated with angiogenesis in a cross-reaction with single xenogeneic homologous protein.

Sign in / Sign up

Export Citation Format

Share Document